Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer

Table 2 Prior regimes of the mCRC patients in the German compassionate-use-program of FTD/TPI

Lead Substance of Combination Treatment (if applicable)	Number of Patients in the German FTD/TPI CUP	% of Patients in the German FTD/TPI CUP
Fluorouracil	220	97.35%
Irinotecan	223	98.67%
Oxaliplatin	199	88.05%
Bevacizumab	193	85.4%
Cetuximab^a	76	33.63%
Panitumumab^a	59	26.11%
Regorafenib	76	33.63%
Aflibercept	63	27.88%
Ramucirumab	4	1.77%
Mitomycin	17	7.52%

^asome patients received both EGFR antibodies
One mCRC patient each received gemcitabine, carboplatin, pembrolizumab, nintedanib or niclosamide
Abbreviations: EGFR, epithelial growth factor receptor; monoclonal antibodies, mabs; not available, n.a

ISSN: 1471-2407